Home About UsAims & Objectives Antimicrobial.Resistance Antimicrobial data Bench Protocols Healthcare.Asso.InfecEducational Material News & Updates Meeting & Events Research Activities Useful Links FAQs Contact Us

 

MULTI-RESISTANT GRAM NEGATIVE RODS

(Acinetobacter spp., Stenotrophomonas maltophilia, Burkholderia cepacia)

A. IDENTIFICATION:

  1. Acinetobacter spp. are gram negative coccobacilli that are non-motile and oxidase negative. They oxidize sugars, but do not ferment, and do not reduce nitrate. Identification to species level is unnecessary for clinical isolates. Nosocomial strains may be multi-drug resistant. Carbapenem resistant strains can occur.

  2. Stenotrophomonas maltophilia are motile, late oxidase positive gram negative rods. They oxidize, but do not ferment sugars. They are DNAse positive, inherently resistant to carbapenems, which may aid in presumptive identification.

  3. Burkholderia cepacia are motile, oxidase variable gram negative rods. They oxidize, but do not ferment sugars. Isolates are characteristically resistant to polymyxins.

B. SENSITIVITY TESTING AND REPORTING

MIC testing is preferable to disk diffusion testing for nonfermenters. However, disk diffusion is more convenient for most clinical laboratories.

QC strains must be tested daily to ensure the validity of test results. The following QC strains must be tested:

  • E. coli ATCC® 29522

  • P. aeruginosa ATCC® 27853

  • E. coli ATCC® 35218 (for β-lactam/β-lactamase inhibitor combinations);

with disk diffusion and MIC results within the ranges proposed by the CLSI.

1.Acinetobacter spp.

  1. Ceftazidime and Imipenem should always be tested and reported.

  2. Other agents may be reported as alternative therapeutic options e.g. Fluoroquinolones, tetracyclines,trimethoprim/sulfamethoxazole, aminoglycosides, etc

  3. Polymyxins may be tested  by measuring MICs (by broth microdilution or agar dilution) for multi-drug resistant isolates.

Preference

Agent

( +disk content where applicable)

Breakpoints

Disk diffusion Zone diameteres

Interpretive standards

MIC (µg/ml)

S

I

R

S

I

R

1st line

CEFTAZIDIME (30 µg)

< 14

15-17

> 18

< 8

16

> 32

1st line

IMIPENEM (10 µg)

< 13

14-15

> 16

< 4

8

> 16

2nd line

PENICILLINS*:

-Piperacillin (100 µg)

 

< 17

 

18-20

 

> 21

 

< 16

 

32-64

 

> 128

2nd line

CEPHALOSPORINS*:

-Cefotaxime (30 µg)

-Ceftriaxone (30 µg)

-Cefepime (30 µg)

 

< 14

< 13

< 14

 

15-22

14-20

15-17

 

> 23

> 21

> 18

 

< 8

< 8

< 8

 

16-32

16-32

16

 

> 64

> 64

> 32

2nd line

Trimethoprim/ sulfamethoxazole (1.25/23.75)

 

 < 10

 

 11-15

 

 > 16

 

< 2/38

  

-

 

> 4/76

2nd line

TETRACYLINES**:

-Tetracycline (30 µg)

-Doxycycline (30 µg)

-Minocycline (30 µg)

 

< 11

< 9

< 12

 

12-14

10-12

13-15

 

> 15

> 13

> 16

 

< 4

< 4

< 4

 

8

8

8

 

> 16

> 16

> 16

2nd line

AMINOGLYCOSIDES*:

-Gentamicin (10 µg)

-Amikacin (30 µg)

-Tobramycin (10 µg)

 

< 12

< 14

< 12

 

13-14

15-16

13-14

 

> 15

> 17

> 15

 

< 4

< 16

< 4

 

8

32

8

 

> 16

> 64

> 16

2nd line

FLUOROQUINOLONES:*

-Ciprofloxacin (5 µg)

-Levofloxacin (5 µg)

 

< 15

< 13

 

16-20

14-16

 

> 21

> 17

 

< 1

< 2

 

2

4

 

> 4

> 8

2nd line

β-LACTAM/ β-LACTAMASE INHIBITOR COMBINATIONS*:

-Ampicillin/sulbactam (10/10 µg)

-Piperacillin/tazobactam (100/10 µg)

-Ticarcillin/ clavulanate (75/10 µg)

 

 

< 11

< 17

< 14

 

 

 12-14

 18-20

 15-19

 

 

> 15

> 21

> 20

 

 

 < 8/4

 < 16/4

 < 16/2

 

 

 16/8

32/4-64/4

32/2-64/2

 

 

 > 32/16

 > 128/4

 > 128/2

3rd line

Polymyxin-B/ Colistin

 

 

 

< 2

-

> 4

  • Alternative antimicrobials in each group are not cross-reportable.

  • Isolates sensitive to tetracycline are usually sensitive to doxycycline and minocycline; however, some tetracycline resistant isolates may be sensitive to either doxycycline and/or minocycline.

2. Stenotrophomonas maltophilia

  1. Trimethoprim/sulfamethoxazole is the therapeutic agent of choice and must always be reported.

  2. Carbapenems should not be tested/ reported.

  3. Other agents may be reported as alternatives e.g., fluoroquinolones, tetracyclines.

  4. Cephems (cephalosporins including ceftazidime), chloramphenicol, and ticarcillin/clavulanate may be reported based on MIC results.

Preference

Agent

( +disk content where applicable)

Breakpoints

Disk diffusion Zone diameteres

Interpretive standards

MIC (µg/ml)

S

I

R

S

I

R

1st line

TRIMETHOPRIM-SULFAMETHOXAZOLE

(1.25/23.75 µg)

 

 

< 10

 

 

11-15

 

 

> 16

 

 

< 2/38

 

 

-

 

 

> 4/76

2nd line

Levofloxacin

< 13

14-16

> 17

< 2

4

> 8

2nd line

Minocycline (30 µg)*

< 14

15-18

> 19

< 4

8

> 16

2nd line

Ticarcillin/clavulanate

 

 

 

< 16/2

32/2-64/2

> 128/2

2nd line

CEPHEMS/ Ceftazidime

(30 µg)

 

 

 

 

< 8

 

16

 

> 32

2nd line

Chloramphenicol

 

 

 

< 8

16

> 32

* Minocycline is the preferable than tetracycline to test against Stenotrophomonas maltophilia strains.

3. Burkholderia cepacia

  1. Trimethoprim/sulfamethoxazole is the therapeutic agent of choice and must always be reported.

  2. Polymyxins should not be tested/ reported.

  3. Other agents may be reported as alternatives e.g. cephems, carbapenems, tetracyclines.

  4. Fluoroquinolones, chloramphenicol, and ticarcillin/clavulanate may be reported based on MIC results.

Preference

Agent

( +disk content where applicable)

Breakpoints

Disk diffusion Zone diameters

Interpretive standards

MIC (µg/ml)

S

I

R

S

I

R

1st line

TRIMETHOPRIM-SULFAMETHOXAZOLE

(1.25/23.75 µg)

 

 

< 10

 

 

11-15

 

 

> 16

 

 

< 2/38

 

 

-

 

 

> 4/76

2nd line

CEPHEMS/ Ceftazidime

(30 µg)

 

< 17

 

18-20

 

> 21

 

< 8

 

16

 

> 32

2nd line

Meropenem (10 µg)

< 15

16-19

> 20

< 4

8

> 16

2nd line

Minocycline (30 µg)*

< 14

15-18

> 19

< 4

8

> 16

2nd line

Ticarcillin/clavulanate

 

 

 

< 16/2

32/2-64/2

> 128/2

2nd line

Levofloxacin

 

 

 

< 2

4

> 8

2nd line

Chloramphenicol

 

 

 

< 8

16

> 32

 

 

 
Copyright @ Antimicrobial Resistance Network 2007, All right reserved
   
Developed By: Faisal Riaz Malik